Fitzsimons Joseph Francis's Form 4 filing
Horizon Quantum Holdings Ltd. (HQ) · filed Sep 15, 2026
- Accession no.
- 0001213900-26-100279
- Filed
- Sep 15, 2026, 9:30 PM ET
- Trade date
- Jun 12-Sep 12, 2026
- Filing delay
- 95 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. It was filed 95 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fitzsimons Joseph FrancisCIK 0002122720 | Director, Officer (Chief Executive Officer), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Class A Ordinary Shares | AGrant or awardAcquired | +229,148 | $0.00 | $0 | 229,148 | Direct | |
| Sep 12, 2026 | Class A Ordinary Shares | MOption exerciseAcquired | +14,321 | $0.00 | $0 | 214,827 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date.
Referenced by the price of 1 transaction in Table I.
- F3
The reported disposition to the Company reflects the settlement in cash of a portion of the RSUs which vested on September 12, 2026, at a price per ordinary share of $15.22, the last reported sales price of the Company's Class A Ordinary Shares on September 11, 2026.
Referenced by the price of 1 transaction in Table I.